Dr. Thompson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
825 Eastlake Ave E
Seattle, WA 98109Phone+1 206-606-2044
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 1982 - 1985- University of WashingtonResidency, Internal Medicine, 1979 - 1982
University of Alabama School of MedicineClass of 1979
Certifications & Licensure
WA State Medical License 1980 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- Interleukin-2 in Treating Patients With Myelodysplastic Syndrome Start of enrollment: 1996 Jan 01
- Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer Start of enrollment: 2013 Feb 15
Publications & Presentations
PubMed
- 166 citationsMelanoma: Cutaneous, Version 2.2021 Featured Updates to the NCCN GuidelinesSusan M. Swetter, John A. Thompson, Mark R. Albertini, Christopher A. Barker, Joel M. Baumgartner
Journal of the National Comprehensive Cancer Network. 2021-04-01 - 222 citationsManagement of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.John A Thompson, Bryan J Schneider, Julie Brahmer, Amaka Achufusi, Philippe Armand
Journal of the National Comprehensive Cancer Network. 2022-04-01 - 290 citationsNCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, Stephanie Andrews, Philippe Armand
Journal of the National Comprehensive Cancer Network. 2020-03-01
Journal Articles
- Phase 1 Trials of Anti-ENPP3 Antibody Drug Conjugates in Advanced Refractory Renal Cell CarcinomasRoberto Pili, John A Thompson, Clinical Cancer Research
Press Mentions
Multidisciplinary Approach for Addressing Immunotherapy-Related ToxicitiesJune 28th, 2019
Alpine Immune Sciences Provides Corporate Update and Reports Full Year 2018 Financial ResultsMarch 18th, 2019- Alpine Immune Sciences Advances Oncology Programs with New ALPN-202 Preclinical Data and Key Additions to Scientific Advisory BoardNovember 9th, 2018
- Join now to see all
Professional Memberships
- Member
- Member
- National Comprehensive Cancer NetworkMember
- Society for Immunotherapy of CancerMember
Other Languages
- French
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
